ALNY vs DSGN
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. DSGN: Design Therapeutics is a biopharmaceutical company pioneering GeneTAC small-molecule therapies to treat the root causes of serious genetic diseases.
Side-by-side fundamentals
| Metric | ALNY | DSGN | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $225.10 | $10.73 | |
| Market cap | $30.1B | $672M | |
| P/E as of 2026-10-21 | 39.22 | n/a | |
| Net margin FY2025, SEC XBRL | +8.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +13.5% | n/a | |
| ROE FY2025, SEC XBRL | +39.8% | -32.8% | ALNY higher |
| ROA FY2025, SEC XBRL | +6.3% | -30.9% | ALNY higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +65.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.81 | 1.19 | |
| 1-year return as of 2026-10-21 close | -52.5% | +90.6% | DSGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.